Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs STOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FDMT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

FDMT Overall Winner 6-Pillar Tally: FDMT 3 – 2 STOK (1 Tie) Matrix Metrics: FDMT 4 – 4 STOK

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Stoke Therapeutics, Inc. (STOK) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas STOK carries 55.8/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin).

  • Composite vs. Pillar Nuance: While STOK currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -913.2% operating margin) and revenue trajectory (+4505.6% vs. +5.9% YoY).
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs STOK
FDMT NASDAQ Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
STOK NASDAQ
Stoke Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$26.54
-0.52% 1D
Market Cap $1.7B
TTM Revenue $28M
Forward P/E N/M
Beta / 30D Vol 0.99β · 47% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 37.0 Fund 52.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 52.6 · SMA20: $26.48 · SMA50: $26.39

6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 STOK)

Columns: Metric · FDMT · STOK
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x 57.0x
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% +5.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $28M
Market Cap $669.3M $1.7B
3. Profitability & Quality FDMT
Gross Margin N/A 100.0%
Operating Margin -222.7% -913.2%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -73.6%
4. Balance Sheet & Cash Flow STOK
Cash Generation (TTM) -$156M -$216M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $106M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STOK
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 82.4% (10th %ile) 63.5% (8th %ile)
Put/Call OI Skew 5.16x (Put-Skewed) 3.80x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (4) vs STOK (4)
Institutional Metric FDMT STOK Criterion Row Edge
Market Capitalization
Scale
$669.3M $1.7B Larger Scale STOK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% +5.9% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% -913.2% Higher Margin FDMT
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin STOK
Return on Equity (ROE)
Capital Efficiency
-56.7% -73.6% Higher ROE FDMT
52-Week Range Position
Momentum
47% ($7–$17) 25% ($22–$40) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 0.99β · 47% Vol Lower Realized Risk STOK
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite STOK
Trailing 12M Revenue (USD)
Operating Scale
$96M $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · 57.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$216M ($106M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STOK +13.85 pp
FDMT: -4.04% · STOK: +9.81%
3M Horizon STOK +3.44 pp
FDMT: -20.86% · STOK: -17.42%
6M Horizon FDMT +47.85 pp
FDMT: +39.27% · STOK: -8.58%
1Y Horizon FDMT +11.53 pp
FDMT: +13.33% · STOK: +1.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue STOK Revenue FDMT Op. Margin STOK Op. Margin Margin Leader
FY2019 $10M N/A -729.4% N/A FDMT
FY2020 $10M N/A -424.0% N/A FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M $10M -3516.5% -841.2% STOK
FY2023 $20M $10M -544.6% -1307.2% FDMT
FY2024 $0M $40M -507678.4% -277.3% STOK
FY2025 $90M $180M -187.2% -11.2% STOK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STOK SURGE
5d in phase · OBV ACCUMULATION
Current IV 63.5%
IV Percentile 8th %ile
Put/Call OI Skew 3.80x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact STOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STOK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -913.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs STOK Key Questions & Quantitative Answers

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) is the stronger overall head-to-head candidate over Stoke Therapeutics, Inc. (STOK) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas STOK carries 55.8/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin). Composite vs. Pillar Nuance: While STOK currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -913.2% operating margin) and revenue trajectory (+4505.6% vs. +5.9% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with STOK at +5.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (100.0% gross margin, -913.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while STOK shifted +1700.0%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STOK.

FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas STOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 57.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus STOK (-73.6% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, STOK carries 63.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 3.80x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.99β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.